TAI'AN, China, Sept. 3 China BiologicProducts, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"),one of the leading plasma-based pharmaceutical companies in the People'sRepublic of China ("PRC"), operating through its indirect majority-ownedsubsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") andChongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equityinvestment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), todayannounced that the Company's management team will attend the upcoming Rodman &Renshaw Annual Global Investment Conference.
The date, time and location of China Biologic's presentation at theconference are as follows:
During the conference, the Company will be available to meet with analystsand portfolio managers. Interested parties and investors who wish to meet withChina Biologic's management may contact firstname.lastname@example.org or call(212) 430-1782. Participation in the Rodman & Renshaw Annual Global InvestmentConference is by invitation only.
About Rodman & Renshaw, LLC.
Rodman & Renshaw, LLC is a full service investment bank dedicated toproviding investment banking services to companies that have significantcapital needs, along with research and sales and trading services to investorclients. Rodman is a leader in the PIPE (private investment in public equity)and RD (registered direct placements) transaction markets according toPrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems,Inc.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirectmajority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. andChongqing Dalin Biologic Technologies Co., Ltd, and its equity investment inXi'an Huitian Blood Products Co., Ltd., is currently the largestnon-state-owned plasma-based biopharmaceutical company in China. The Companyis a fully integrated biologic products company with plasma collection,production and manufacturing, research and development, and commercialoperations. The Company's plasma-based biopharmaceutical products areirreplaceable during medical emergencies, and are used for the prevention andtreatment of various diseases. It sells its products to hospitals and otherhealthcare facilities in China.Date: Thursday, September 10, 2009 Time: 12.05 p.m. Eastern Time Venue: Asia Track New York Palace Hotel New York, NY
SOURCE China Biologic Products, Inc.